NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Sellas Life Sciences Group, Inc. SLS
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.25
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-66.9%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -0.25
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-66.9%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-54.9%
Each USD of equity lost 67 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 78.3M
total assets, end of FY2025
Total assetsUSD 78.3M
EquityUSD 70.9M
CashUSD 71.8M
Current ratio10.72×
Equity funds 90% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
·
·
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.25
−0.50
−1.34
−2.13
−1.34
−2.11
−10.92
−157.72
−10.44
−18.66
−8.23
−6.13
−0.85
−0.56
−0.32
−0.67
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
−0
−2
−0
·
·
·
·
·
·
·
ROE %
−66.9
−4147.9
·
−327.8
−85.7
−98.4
−340.3
−756.5
·
·
−515.4
−170.5
−455.8
−184.7
−183.1
−493.5
Shares out B
0.15
0.07
0.03
0.02
0.02
0.01
0.01
0.00
0.01
0.00
0.01
0.11
0.11
0.08
0.05
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed